A person with polycythemia and normal or low erythropoietin levels may have polycythemia vera, which is a rare type of blood cancer. In any case, healthcare professionals will use additional tests to help clarify their results and confirm their diagnosis. Blood transfusions using healthy, erythropoietin-rich blood may help treat some forms of anemia from chronic kidney failure. Sometimes, however, a blood transfusion is not possible.
When this is the case, a doctor may recommend synthetic injections called erythropoietin-stimulating agents ESAs. Doctors can deliver these drugs through an injection that activates the bone marrow in the same way that natural erythropoietin does, stimulating red blood cell production. ESA injections can effectively treat some of the symptoms of kidney failure. In fact, the author of one article notes that ESA injections are by far most common in people with kidney failure.
Injections can help restore erythropoietin and red blood cell levels, but it may take time for levels to build up in the blood. It can take weeks, for example, before the person notices a reduction in their symptoms.
ESA injections also have the potential for abuse. Some athletes looking for a competitive edge may seek injections of synthetic erythropoietin to increase the red blood cells and oxygen levels in their body. However, adding more erythropoietin to a healthy body can be dangerous and increase the risk of side effects. ESA injections can help treat a number of conditions, but they do have the potential for side effects and risks. Healthy people who abuse ESA injections may be more at risk of these side effects, as the unnecessary increase of red blood cells may make the blood thicker and more prone to clotting.
In some cases of use among people with cancer, the ESA may cause the tumor to grow. Therefore, these people may only receive ESAs for a short time to help prevent the symptoms of chemotherapy. Abnormal erythropoietin levels may indicate an issue in the kidneys or bone marrow.
Tests for erythropoietin levels can help doctors identify the underlying cause of blood conditions. Such causes include anemia. In people with low erythropoietin levels due to kidney disease or other conditions, ESA injections may help treat the issue.
ESA injections carry some risks, however, as they make the blood thicker and more prone to clotting. Also, healthy people who abuse these injections may be at a higher risk of more serious complications.
Anyone who is uncertain about their diagnosis or treatment should talk to their doctor about all the treatment options before making any changes. Chronic kidney disease is a progressive loss of kidney function. Often the symptoms are not noticeable until the disease is at kidney failure, so it…. Iron is a vital mineral in the body, central to transporting oxygen around the body in the hemoglobin.
A shortage of iron can cause health problems…. Autoimmune hemolytic anemia, or AIHA, is an immune condition where the immune system destroys red blood cells. Within the kidneys, the local venous oxygen tension which reflects the ratio of oxygen supply to oxygen consumption is measured and transformed into a signal that regulates the formation of EPO.
However, the mechanism by which a decrease of oxygen delivery to the kidneys is linked to an enhanced EPO gene expression is not yet known. Two possible mechanisms of regulation are discussed: First, renal hypoxia could lead to enhanced formation of metabolic mediators, for example prostaglandins or adenosine, which might stimulate EPO gene transcription by increasing cellular levels of second messenger molecules.
Second, some kind of molecular 'oxygen receptor' such as a heme protein, that controls EPO formation by an oxygen-dependent conformational change, could mediate signal transduction. Abstract The glycoprotein hormone erythropoietin EPO counteracts tissue hypoxia by increasing the systemic oxygen-carrying capacity.
Abstract Erythropoietin Epo , which is produced by the kidney in the adult and by the liver in the fetus, increases red blood cells by supporting the survival of erythroid progenitor cells and stimulating their differentiation and proliferation via binding to Epo receptor EpoR.
Publication types Research Support, Non-U. Gov't Review.
0コメント